Johann K. Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M

Slides:

Advertisements

Similar presentations

Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia Michael R. Grunwald, Li-Hui.

Advertisements

Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia Michael R. Verneris, Mary Eapen,

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens by Menachem Bitan,

Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Bone Marrow Transplantation for Diamond-Blackfan Anemia

Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

Biology of Blood and Marrow Transplantation

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

The Influence of Stem Cell Source on Chronic-GvHD Free, Leukemia Free Transplant Survival in Pediatric Patients with Acute Myeloid Leukemia Amy K. Keating,

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism Mary.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS- Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous.

A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates that Unrelated Donor Transplants are as.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age Lujia Dong,

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Blood and Marrow Transplant Handbook

Troy C. Lund, Sara S. Cathey, Weston P

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Patrick J. Stiff, Manza-A. Agovi, Karen H

Treatment versus Transplant for Challenging Hematologic Disorders

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

Mary Eapen Biology of Blood and Marrow Transplantation

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome Johann K. Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M. Camitta, Ka Wah Chan, Miguel A. Diaz Perez, Christopher Fraser, Thomas G. Gross, John T. Horan, Alana A. Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie Lehmann, Tracey O'Brien, Michael A. Pulsipher, Franklin O. Smith, Mei-Jie Zhang, Mary Eapen, Paul A. Carpenter Biology of Blood and Marrow Transplantation Volume 19, Issue 6, Pages 893-897 (June 2013) DOI: 10.1016/j.bbmt.2013.02.017 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) The 3-year probabilities of TRM: 24% (95% CI, 9% to 44%) and 15% (95% CI, 8% to 24%) for DS-AML and non-DS AML, respectively (P = .04). (B) The 3-year probabilities of relapse: 62% (95% CI, 41% to 81%) and 37% (95% CI, 27% to 48%), for DS-AML and non-DS AML, respectively (P < .001). (C) The 3-year probabilities of DFS: 14% (95% CI, 3% to 32%) and 48% (95% CI, 37% to 59%) for DS-AML and non-DS AML, respectively (P < .001). (D) The 3-year probabilities of overall survival: 21% (95% CI, 6% to 42%) and 52% (95% CI, 41% to 63%), for DS-AML and non-DS AML, respectively (P < .001). Biology of Blood and Marrow Transplantation 2013 19, 893-897DOI: (10.1016/j.bbmt.2013.02.017) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions